Unafraid of Challenges, Bravely Moving Forward | Hycells Bio Celebrates Its 2nd Anniversary


 

June 30, 2023, marked the mid-year review day for the Hycells Initiative—and coincidentally also the second anniversary of Hycells’s founding. To celebrate this special and meaningful occasion, the team decided to get together a bit early. Two years may seem like but a fleeting moment in the grand sweep of history, yet for Hycells, those two years have been extraordinarily precious and truly unique.

 

Since its inception, Heyou has grown from scratch to a steadily expanding enterprise. Upholding the core values of talent as the foundation, quality as the priority, and innovation as the driving force, the company has advanced steadily, one step at a time, with unwavering commitment and practicality.

 

Today, amid a broader domestic economic downturn, the pharmaceutical R&D sector is no exception. While investor caution has slowed momentum, it has not halted the industry’s progress; the current economic chill is prying away the sector’s excesses, and the windfall benefits of rapid growth are gradually fading. Adversity tests the true strength of every individual and every company—after all, challenges can spur rapid development.

 

Over the past two years, Hycells has focused on personal growth and continuous internal development, steadfastly leveraging technological innovation as the core driver to constantly optimize the technology service platform and streamline operational processes. At the same time, Hycells has deepened compliance governance, advanced the cultivation of a compliance-oriented corporate culture, strengthened internal management mechanisms, and solidified the foundation for the company’s sustainable development.

 

640.jpg

The photo shows work reports from various departments by Hycells’s colleagues.

 

 640 (1).jpg

The photo captures a leisurely moment after the mid-year report, with some colleagues still deeply engrossed in work.

 

 Image

 

On the occasion of the second anniversary of HeYou’s founding, we celebrate with joy!

We are deeply grateful for the trust and support of every partner who has stood by us every step of the way!

Thank you to every Hycells team member for your diligent work and unwavering dedication!

The road ahead remains fraught with obstacles—only the brave can prevail!

May we always stay true to our original aspirations, fear no difficulties, and forge ahead with courage!

 

 640 (2).jpg

The photo shows the celebration ceremony for the second anniversary of Hycells.

 

Related News


(II) Security Assurance Section | Safety First, Defense Prioritized

Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.


(1) Compliance and Traceability Section | Establishing a Foundation of Compliance, Ensuring Source Tracing

This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.


Compliance as the Foundation, Safety as the Core | The Steadfast Commitment and Confidence Behind Heyou Sheng’s Serum Substitute

In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.


A novel mechanism by which iron overload in the tumor microenvironment triggers ferroptosis in CD8⁺ T cells | Guangzhou National Laboratory publishes in Nature Communications, revealing a key pathway of immune evasion (IF: 18.2)

Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.


Hycells Recruitment | Never Stop Exploring, Never Stop Innovating

The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.


3.0 High-Efficiency Version of HiXpan® NK Serum-Free Culture Kit | Chapter 4: Comprehensive Overview of Customer-Specific Culture Data Across Multiple Scenarios

The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.